GenBody Genetics Receives Designation as 'Good Laboratory Animal Production Facility' from Ministry of Food and Drug Safety

GenBody Genetics (Geochang) has been officially designated as a Good Laboratory Animal Production Facility (KELAS) by the Ministry of Food and Drug Safety.

According to GenBody Genetics on June 9, the Good Laboratory Animal Production Facility certification is a national accreditation awarded to institutions equipped with the capability to produce and supply laboratory animals under an internationally recognized quality control system for use in various bio research and development processes, including new drug development, vaccines, in vitro diagnostic medical devices, and advanced biopharmaceuticals.

With this designation, GenBody Genetics has secured a laboratory animal production and management system recognized by the Korean government, establishing a foundation to stably supply more reliable research laboratory animals to domestic research institutions and pharmaceutical and biotech companies.

Laboratory animals play a key role throughout the entire new drug development process, including non-clinical research, toxicity testing, efficacy evaluation, and safety validation. As Korea’s bioindustry is rapidly growing, particularly in fields such as new drug development, cell and gene therapies, in vitro diagnostic devices, and precision medicine, the demand for high-quality laboratory animals continues to steadily increase.

GenBody Genetics has developed a systematic disease control system at the SPF level and a standardized breeding environment at its production facility located in Geochang-gun, Gyeongsangnam-do. The company has also continued to advance its operational system to produce laboratory animals of a quality suitable for research purposes, all while adhering to animal welfare principles.

Looking ahead, GenBody Genetics plans to expand its research support platform beyond laboratory animal production to include support for non-clinical research, genetic analysis, and disease model development, thereby strengthening the foundation for the growth of Korea’s bioindustry and evolving into a research service provider of global standards.

CEO Jeong Jeomgyu stated, “We will do our utmost to provide the optimal research environment and high-quality laboratory animals so that domestic researchers and biopharmaceutical companies can conduct more stable and reproducible research,” adding, “We will continue to expand research infrastructure in line with international standards and grow as a research partner that contributes to enhancing the global competitiveness of Korea’s bioindustry.”

This content was produced with the assistance of AI translation services.